But Where Will We Stay? Traveling for Cancer Treatment

Every day more than 3,500 people in the United States are diagnosed with cancer. Many must travel to cancer centers specializing in their particular treatment needs. Combined with the millions who are already fighting this disease, it means tens of thousands of cancer patients every day throughout the United States are looking for a suitable place to stay.

Joe's House is a nonprofit organization providing a nation-wide online service that helps cancer patients and their families find lodging near treatment centers. Founded in 2003, Joe’s House was conceived after Ann Calahan’s first husband, Joe Warnecke, died of cancer. Joe battled the disease for six years. During those six years, Ann and Joe had difficulty finding appropriate accommodations in unfamiliar cities. Ann vowed to correct this problem.

Joe's House feels that patients deserve an accommodation expert to help them with their travel needs. They list various types of lodging throughout the United States. Details on each lodging facility are available with information on amenities, rates, and reservation methods and requirements.

For more information, contact Joe’s House (http://www.joeshouse.org) at info@joeshouse.org or call 877-JOESHOU (877-563-7468).

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap